Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma (Japan)
jRCT2080221640Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial of elotuzumab in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Started Nov 2011; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080221640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221640.